42C.SI IX Biopharma
Market Closed 08-07 17:16:00 SGT Delay
0.5650
+0.0200
+3.67%
High0.5700Low0.5300Vol20.85M
Open0.5450D1 Closing0.5450Amplitude7.34%
Mkt Cap615.29MTradable Cap270.24MTotal Shares1.09B
T/O11.61MT/O Rate4.36%Tradable Shares478.30M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

LGI Accumulates Shares in Valuetronics & iX Biopharma
sgx.com  ·  08-03
LGI Accumulates Shares in Valuetronics & iX Biopharma
OCBC emerges as substantial shareholder of iX Biopharma
Teo Zheng Long  ·  07-27
OCBC emerges as substantial shareholder of iX Biopharma
iX Biopharma issues 1.36 million new shares from warrant exercises ahead of July 17 expiry
SGX Filings  ·  07-20
iX Biopharma issues 1.36 million new shares from warrant exercises ahead of July 17 expiry
IX Biopharma Issues 1,362,355 Shares from Warrant Exercises at S$ 0.06
Reuters  ·  07-20
IX Biopharma Issues 1,362,355 Shares from Warrant Exercises at S$ 0.06
iX Biopharma issues 2.8 million new shares on warrant exercise ahead of warrant expiry
SGX Filings  ·  07-17
iX Biopharma issues 2.8 million new shares on warrant exercise ahead of warrant expiry
IX Biopharma Issues 2,774,778 Shares from Warrant Exercises at S$ 0.06
Reuters  ·  07-17
IX Biopharma Issues 2,774,778 Shares from Warrant Exercises at S$ 0.06
iX Biopharma Reports 92% Warrants Exercise
MT Newswires  ·  07-16
iX Biopharma Reports 92% Warrants Exercise
iX Biopharma issues 11.7 million new shares after warrant exercises
SGX Filings  ·  07-15
iX Biopharma issues 11.7 million new shares after warrant exercises
IX Biopharma Issues 11,734,627 Shares After Warrants Exercised at S$ 0.06
Reuters  ·  07-15
IX Biopharma Issues 11,734,627 Shares After Warrants Exercised at S$ 0.06
iX Biopharma issues 2.92 million new shares after warrant exercise
SGX Filings  ·  07-14
iX Biopharma issues 2.92 million new shares after warrant exercise
iX Biopharma issues 6.32 million new shares after warrant exercises
SGX Filings  ·  07-07
iX Biopharma issues 6.32 million new shares after warrant exercises
IX Biopharma Issues 6,315,859 Shares from Warrant Conversions at S$ 0.06
Reuters  ·  07-07
IX Biopharma Issues 6,315,859 Shares from Warrant Conversions at S$ 0.06
IX Biopharma Warrants Set to Expire July 17, 2026
Reuters  ·  07-06
IX Biopharma Warrants Set to Expire July 17, 2026
iX Biopharma sets out FY2026 roadmap, confirms US$41 million DoD contract and consumer spinoff
SGX Filings  ·  07-03
iX Biopharma sets out FY2026 roadmap, confirms US$41 million DoD contract and consumer spinoff
IX Biopharma Restructures Consumer Business, Transfers Unit to New Entity Ligo Pharma
Reuters  ·  07-03
IX Biopharma Restructures Consumer Business, Transfers Unit to New Entity Ligo Pharma
iX Biopharma issues 4.42 million new shares after warrant exercises
SGX Filings  ·  06-30
iX Biopharma issues 4.42 million new shares after warrant exercises
IX Biopharma Issues 4,423,414 Shares on Warrant Exercises at S$ 0.06 Each
Reuters  ·  06-30
IX Biopharma Issues 4,423,414 Shares on Warrant Exercises at S$ 0.06 Each
iX Biopharma issues 2.39 million new shares following warrant exercise
SGX Filings  ·  06-24
iX Biopharma issues 2.39 million new shares following warrant exercise
IX Biopharma Issues 2,391,214 Shares from Warrant Exercises at S$ 0.06 Each
Reuters  ·  06-24
IX Biopharma Issues 2,391,214 Shares from Warrant Exercises at S$ 0.06 Each
iX Biopharma issues exercise notice for warrants expiring Jul, 18 2026
SGX Filings  ·  06-23
iX Biopharma issues exercise notice for warrants expiring Jul, 18 2026

Introduction

Company Name.
IX Biopharma
Affiliated Markets:
SGX
Listing Date:
--
Main Business:
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
Issue price:
--